Data from the EMBARK trial suggest patients may have functional improvements taking the gene therapy between 8 and 9 years old.

The analysis by Ontada tracked testing rates withing the US Oncology Network for PD-L1, FGFR2/3, and HER2 biomarkers over 10 years.

In a Phase Ia trial in ovarian cancer, a strong neutralizing antibody response correlated with better disease control and ...

The firms launched the global Phase II bladder cancer trial for autogene cevumeran after seeing early success in pancreatic ...

The European Commission approval was based on results showing the immunotherapy regimen improved event-free survival in a Phase III trial.